rhBMP-2 protects against reoperation for pseudoarthrosis and/or instrumentation failure: A matched case-control study of 448 patients

Mohamed Macki, Sbaa Syeda, Panagiotis Kerezoudis, Ali Bydon, Timothy F. Witham, Daniel M. Sciubba, Jean Paul Wolinsky, Mohamad Bydon, Ziya Gokaslan

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

The objective of this independent study is to determine the impact of recombinant human bone morphogenetic protein 2 (rhBMP-2) on reoperation for pseudarthrosis and/or instrumentation failure. A nested case-control study of first-time posterolateral, instrumented fusion of the lumbar spine for degenerative spinal disease was undertaken. Cases of reoperation for pseudoarthrosis and/or instrumentation failure were assigned to controls, who did not experience the primary outcome measure at the time of reoperation. Cases and controls were matched on number of interspaces fused and inclusion of interbody. Predictors of reoperation for pseudoarthrosis and/or instrumentation failure were assessed with a conditional logistical regression controlling for rhBMP-2, age, obesity, and smoking. Of the 448 patients, 155 cases of reoperation for pseudoarthrosis and/or instrumentation were matched with 293 controls. Twenty-six percent of first-time surgeries included rhBMP-2, which was statistically more commonly used in the control cohort (33.11%) versus the case cohort (12.90%) (Unadjusted odds ratio [ORunadj] = 0.28) (95% confidence interval [CI]: 0.16–0.49). Following a multivariate analysis controlling for age, obesity, and smoking, the rhBMP-2 recipients incurred a 73% lower odds of reoperation for pseudoarthrosis and/or instrumentation failure (95% CI, 0.15–0.48). Neither sarcomatous nor osseous neoplasm was detected in the study population. Mean follow up did not differ between the cases (81.57 ± standard deviation [SD] 4.98 months) versus controls (74.75 ± 2.49 month) (ORunadj = 1.01) (95% CI: 1.00–1.01). rhBMP-2 in lumbar fusion constructs protects against reoperation for pseudoarthrosis and/or instrumentation failure. However, the decision to include fusion supplements should be weighted between surgical determinants and clinical outcomes.

Original languageEnglish (US)
Pages (from-to)99-103
Number of pages5
JournalJournal of Clinical Neuroscience
Volume32
DOIs
StatePublished - Oct 1 2016

Keywords

  • Bone morphogenetic protein
  • Instrumentation failure
  • Pseudarthosis
  • Reoperation

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'rhBMP-2 protects against reoperation for pseudoarthrosis and/or instrumentation failure: A matched case-control study of 448 patients'. Together they form a unique fingerprint.

  • Cite this

    Macki, M., Syeda, S., Kerezoudis, P., Bydon, A., Witham, T. F., Sciubba, D. M., Wolinsky, J. P., Bydon, M., & Gokaslan, Z. (2016). rhBMP-2 protects against reoperation for pseudoarthrosis and/or instrumentation failure: A matched case-control study of 448 patients. Journal of Clinical Neuroscience, 32, 99-103. https://doi.org/10.1016/j.jocn.2016.03.025